Literature DB >> 23804192

Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.

Maria Blomberg1, Christian Dehlendorff, Christian Munk, Susanne K Kjaer.   

Abstract

BACKGROUND: A reduction in the incidence of genital warts (GWs) is one of the first markers of the effectiveness of vaccination against human papillomavirus (HPV) at the population level. The aim of this cohort study was to use individual information on HPV vaccination status to assess the effect on risk of GWs.
METHODS: Population-based registries were used to identify all girls in the birth cohorts 1989-1999 in Denmark, and information about HPV vaccination was obtained for the period 2006-2012. The cohort was linked to incident cases of GWs, and vaccinated and unvaccinated girls were compared using Cox proportional hazards models.
RESULTS: A total of 248 403 girls were vaccinated. The relative risk of GWs among girls who had received at least 1 dose of vaccine compared with unvaccinated girls was 0.12, 0.22, 0.25, and 0.62 for those born in 1995-1996, 1993-1994, 1991-1992, and 1989-1990, respectively (P for trend < .0001). No GWs occurred among vaccinated girls in the youngest birth cohort (1997-1999).
CONCLUSIONS: The strong, highly significant reduction in the occurrence of GWs among vaccinated girls indicates an early and marked population effect of the national HPV vaccination program and may forecast a similar effect on cervical precancerous lesions.

Entities:  

Keywords:  condyloma acuminata; epidemiology; genital warts; human papillomavirus; vaccination

Mesh:

Substances:

Year:  2013        PMID: 23804192     DOI: 10.1093/cid/cit436

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Addressing HPV vaccine myths: practical information for healthcare providers.

Authors:  Robert A Bednarczyk
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

2.  Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Authors:  Vladimir Gilca; Chantal Sauvageau; Gitika Panicker; Gaston De Serres; Manale Ouakki; Elizabeth R Unger
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

3.  High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.

Authors:  Anna R Giuliano; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Louvina E van der Laan; Mary Papenfuss; Susan Engelbrecht; Maarten F Schim van der Loeff; Staci L Sudenga; Benji N Torres; Siegfried Kipping; Douglas Taylor
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

4.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.

Authors:  Partha Basu; Neerja Bhatla; Twalib Ngoma; Rengaswamy Sankaranarayanan
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

Review 6.  Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.

Authors:  Mariam El-Zein; Lyndsay Richardson; Eduardo L Franco
Journal:  J Clin Virol       Date:  2015-11-18       Impact factor: 3.168

Review 7.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071

Review 8.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

Review 9.  Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.

Authors:  Luciano Mariani; Patrizia Vici; Barbara Suligoi; Giovanni Checcucci-Lisi; Rosybel Drury
Journal:  Adv Ther       Date:  2015-01-27       Impact factor: 3.845

10.  Incidence of anogenital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system.

Authors:  Feixue Wei; Wei Sheng; Xin Wu; Kai Yin; Jian Lan; Yue Huang; Xinjing Ma; Ya Zheng; Sijie Zhuang; Shoujie Huang; Yingying Su; Mingqiang Li; Ting Wu; Jun Zhang; Ningshao Xia
Journal:  Emerg Microbes Infect       Date:  2017-12-20       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.